确定复杂性尿路感染及相关菌血症住院患者的最佳治疗疗程
该观察性研究纳入美国24家医院1099例复杂性尿路感染合并菌血症住院患者,比较7天、10天和14天抗生素疗程。10天与14天复发感染 odds 无差异(aOR 0.99,95%CI 0.52-1.87);7天较14天复发 odds 升高(aOR 2.54,95%CI 1.40-4.60),但限定于静脉β-内酰胺或高生物利用度口服药患者后差异不再持续(aOR 0.76,95%CI 0.38-1.52)。
要点
- 10天与14天疗程复发感染 odds 无差异(aOR 0.99,95%CI 0.52-1.87)。
- 7天较14天复发 odds 升高(aOR 2.54,95%CI 1.40-4.60)。
- 使用静脉与口服生物利用度相当的抗生素时,7天疗程似乎有效。
核心结论
- 当使用静脉与口服生物利用度相当的抗生素时,7天抗生素似乎对复杂性尿路感染住院患者有效;所有其他患者可能需要10天。
研究设计与样本
- 在美国24家医院进行的观察性研究,纳入年龄≥18岁的复杂性尿路感染患者,为增加真实感染可能性,资格限于合并菌血症者。
- 采用倾向评分进行逆概率治疗加权分析,共1099例患者符合标准,分别接受7天(n=265)、10天(n=382)或14天(n=452)治疗。
主要发现
- 主要结局为完成治疗后≤30天内同一菌种复发感染;10天与14天疗程复发感染 odds 无差异(aOR 0.99;95%CI 0.52-1.87)。
- 7天较14天疗程复发感染 odds 升高(aOR 2.54;95%CI 1.40-4.60)。
- 限定于627例持续静脉β-内酰胺治疗或转换为高生物利用度口服药的患者,7天与14天结局差异不再持续(aOR 0.76;95%CI 0.38-1.52)。
- 76例复发感染患者中,7天、10天和14天组分别有2例(11%)、2例(10%)和10例(36%)为耐药感染(P=0.10)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data are available to guide effective antibiotic durations for hospitalized patients with complicated urinary tract infections (cUTIs). METHODS: We conducted an observational study of patients ≥18 years at 24 US hospitals to identify the optimal treatment duration for patients with cUTI. To increase the likelihood patients experienced true infection, eligibility was limited to those with associated bacteremia. Propensity scores were generated for an inverse probability of treatment weighted analysis. The primary outcome was recurrent infection with the same species ≤30 days of completing therapy. RESULTS: 1099 patients met eligibility criteria and received 7 (n = 265), 10 (n = 382), or 14 (n = 452) days of therapy. There was no difference in the odds of recurrent infection for patients receiving 10 days and those receiving 14 days of therapy (aOR: .99; 95% CI: .52-1.87). Increased odds of recurrence was observed in patients receiving 7 days versus 14 days of treatment (aOR: 2.54; 95% CI: 1.40-4.60). When limiting the 7-day versus 14-day analysis to the 627 patients who remained on intravenous beta-lactam therapy or were transitioned to highly bioavailable oral agents, differences in outcomes no longer persisted (aOR: .76; 95% CI: .38-1.52). Of 76 patients with recurrent infections, 2 (11%), 2 (10%), and 10 (36%) in the 7-, 10-, and 14-day groups, respectively, had drug-resistant infections (P = .10). CONCLUSIONS: Seven days of antibiotics appears effective for hospitalized patients with cUTI when antibiotics with comparable intravenous and oral bioavailability are administered; 10 days may be needed for all other patients.
引用
- McAteer J, Lee JH, Cosgrove SE, et al. Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia. Clin Infect Dis. 2023. PMID: 36633559. doi:10.1093/cid/ciad009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。